AMRX
Amneal Pharmaceuticals, Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2009-11-18
$20.21
-0.23 (-1.13%)
last quote
Want the full multi-source brief on AMRX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$20.21
High
$20.80
Low
$19.68
Previous close
$20.44
Fundamentals
Market cap
$7.01B
P/E (TTM)
44.58x
P/S (TTM)
2.25x
P/B
140.74x
Gross margin
39.32%
Operating margin
14.56%
Net margin
5.05%
Rev growth (YoY)
9.28%
EPS growth (YoY)
7506.35%
ROE
174.61%
52W high
$21.68
52W low
$10.06
Beta
1.21x
Industry peers
by market cap
Recent SEC filings
CIK 1723128filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 17h
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
Amneal Pharmaceuticals (NASDAQ:AMRX) reported third-quarter 2026 revenue of $863 million, up 10% from a year earlier, as growth in affordable medicines and specialty products more than offset an expected decline at its AvKARE business. Adjusted EBITDA rose 30% to $207 million, while adjusted earning
Yahoo · 20h
NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View
Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.
Yahoo · 20h
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.
Yahoo · 20h
Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.
Yahoo · 21h
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
SeekingAlpha · 21h
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2026 Earnings Call November 3, 2026 8:30 AM ESTCompany ParticipantsAnthony DiMeo - Head/VP of Investor...
Yahoo · 22h
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ChartMill · 23h
Amneal Pharmaceuticals (NASDAQ:AMRX) Beats Q3 Estimates but Cash-Flow Guidance Weighs on Shares
Amneal Q3 2026 revenue and EPS beat estimates and guidance rose, but weaker cash-flow outlook and acquisition costs weighed on shares.
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial